# Arlocabtagene Autoleucel

Source: https://onco.cc/drugs/arlocabtagene-autoleucel/  
OnCo record `arlocabtagene-autoleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Arlocabtagene Autoleucel is an experimental CAR-T cell therapy from Juno Therapeutics, a Bristol-Myers Squibb in phase 3 trials for multiple myeloma, aimed at GPRC5D.

## Summary

Arlocabtagene Autoleucel (CC-95266, BMS-986393) is a CAR-T cell therapy developed by Juno Therapeutics, a Bristol-Myers Squibb. Its target is GPRC5D (the sponsor names GPRC5D). The sponsor states: Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)), in multiple myeloma. The largest, NCT06615479, plans to enrol 440 participants with primary completion expected 2027-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: Arlo-cel; GPRC5D CAR T cells
- Tags: pipeline; ctgov-ingest
- Code: CC-95266, BMS-986393
- Modality: CAR-T cell therapy
- Mechanism: Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients.

## Sources

- ClinicalTrials.gov: trials of Arlocabtagene Autoleucel: https://clinicaltrials.gov/search?intr=CC-95266

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- targets: [GPRC5D](https://onco.cc/targets/gprc5d/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)](https://onco.cc/trials/quintessential-2/), [Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct06297226/)

---
JSON: https://onco.cc/api/v1/entities/arlocabtagene-autoleucel.json